SWOG clinical trial number
S0349
Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab, or Rituximab and G3139 Phosphorothioate Oligonucleotide (BCL-2 Antisense - NSC-683428) Therapy for Young Patients (< Age 60) with Advanced Stage Diffuse Large B-cell NHL of Low and Low-Intermediate IPI Risk
Closed
Phase
Accrual
10%
Abbreviated Title
NON-HODGKIN'S: CHOP plus G3139 for Adv Stage Large B-cell of Low and Low-Int IPI Risk
Activated
03/01/2004
Closed
05/15/2006
Participants
Research committees
Lymphoma
Treatment
Rituximab
G3139 Phosphorothioate Oligonucleotide
CHOP
Eligibility Criteria Expand/Collapse
Previously untreated Stage III, IV or buly Stage II diffuse large B-cell non-Hodgkin's lymphoma (NHL); CD-20 positive; Path review required; Age < 60; IPI score of 0 or 1; bidimen meas dz; CT scan of chest and CT scan of abdomen/pelvis; bone marrow aspirate and biopsy; no clinical evidence of CNS involvement; no prior dx of indolent lymphoma; no prior chemo, RT or antibody tx for lymphoma; Zubrod PS 0-2; ejection fraction >/= 45% by MUGA or an echo with no significant abnormalities; LDH must be known; no known HIV; patients must not need supplemental oxygen.
Other Clinical Trials
SWOG Clinical Trial Number
S2308
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
S2207
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
12%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase